Taiho Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.taihooncology.com
Clinical Trials
96
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (93 trials with phase data)• Click on a phase to view related trials
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
- Conditions
- Advanced/Metastatic Cancer
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06506955
- Locations
- 🇫🇷
Institut De Cancerologie Strasbourg, Strasbourg, France
🇺🇸University of California, San Francisco (UCSF), San Francisco, California, United States
🇫🇷Institut Paoli-Calmettes, Marseille, France
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
- Conditions
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT05973773
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val-de-Marne, France
🇲🇽Clínica Integral Internacional de Oncología S de RL de CV, Mirador, Puebla, Mexico
🇲🇽FAICIC Clínical Research, Veracruz, Mexico
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- Conditions
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT05967689
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope - Duarte, Duarte, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
- Conditions
- Esophageal Squamous Cell CancerLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerSiewert Type 1 GEJ CancerPancreatic CancerEsophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05945823
- Locations
- 🇺🇸
University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States
🇺🇸Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
A Study of TAS3351 in NSCLC Patients With EGFRmt
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: TAS3351 oral administration
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05765734
- Locations
- 🇺🇸
Georgetown University - Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next